Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Not Applicable

Active, not recruiting

Conditions: Leukemia

Interventions: Genetic: KIR genotyping
Genetic: HLA genotyping

First Posted Date: 2015-05-21

Last Posted Date: 2024-02-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 511

Registration Number: NCT02450708

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 7 locations

Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Pembrolizumab
Radiation: Radiotherapy
Procedure: Radiofrequency ablation

First Posted Date: 2015-05-07

Last Posted Date: 2024-04-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT02437071

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies

Not Applicable

Active, not recruiting

Conditions: Lung Cancer

Interventions: Procedure: Bronchoscopic Implantation
Device: Cone-Beam CT-Guided
Radiation: stereotactic body radiation treatments

First Posted Date: 2015-05-05

Last Posted Date: 2024-11-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT02434809

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, West Harrison, New York, United States

Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

Not Applicable

Active, not recruiting

Conditions: Recurrent Brain Metastases
Progressive Brain Metastases

Interventions: Drug: Meclofenamate

First Posted Date: 2015-04-29

Last Posted Date: 2024-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT02429570

Locations: 🇺🇸
Baptist Health South Florida, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Mocetinostat Plus Brentuximab Vedotin

First Posted Date: 2015-04-29

Last Posted Date: 2022-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT02429375

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Phase 2

Completed

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer

Interventions: Radiation: external beam radiation therapy
Drug: cisplatin
Procedure: Biopsy of Target Tumor

First Posted Date: 2015-04-21

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02422498

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment

Recruiting

Conditions: Radiation Therapy

Interventions: Device: MRI or CT

First Posted Date: 2015-04-21

Last Posted Date: 2025-01-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 567

Registration Number: NCT02422550

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

and more 4 locations

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Not Applicable

Recruiting

Conditions: Malignant Solid Tumors

Interventions: Drug: Hyperpolarized Pyruvate

First Posted Date: 2015-04-20

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 109

Registration Number: NCT02421380

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1

Active, not recruiting

Conditions: Malignant Pleural Disease
Lung Cancer
Metastases
Mesothelioma
Breast Cancer

Interventions: Genetic: iCasp9M28z T cell infusions
Drug: pembrolizumab
Drug: cyclophosphamide

First Posted Date: 2015-04-10

Last Posted Date: 2024-05-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 113

Registration Number: NCT02414269

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Follow-Up), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent and Follow-Up), Montvale, New Jersey, United States

and more 3 locations

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Not Applicable

Completed

Conditions: Glioblastoma

Interventions: Drug: 89Zr-J591
Device: PET/CT Scan
Device: MRI
Other: Blood draw

First Posted Date: 2015-04-07

Last Posted Date: 2019-03-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT02410577

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Home Terms & Conditions Privacy Policy